Medtronic Clinches Reimbursement Wins and FDA Clearance as MiniMed Spinoff Exchange Period Ends
Published on 10/10/2026 at 20:10 | Editorial boerse-global.de
Medtronic's diabetes separation reached its decisive moment on Friday, when the exchange offer tied to the MiniMed spinoff expired. Shareholders who tendered received a final ratio of 4.5939 MiniMed shares for every Medtronic share submitted — a figure the company locked in on Wednesday. The offer covered as many as 225,361,295 MiniMed shares in total.
The transaction marks the closing chapter of Medtronic's effort to hive off its diabetes unit, a move designed to sharpen capital allocation toward cardiovascular and interventional specialties. With the exchange period now over, the split-off enters its final phase.
Billing Codes and FDA Clearance Reshape the Pipeline
While the spinoff dominated headlines, Medtronic was quietly stacking up regulatory and reimbursement victories across its surgical and interventional franchises.
On Wednesday, the FDA granted 510(k) clearance for navigated ApexCut EM blades used in sinus surgery. The instruments link powered surgical tools directly to the company's Stealth AXiS ENT navigation system — a pairing that could streamline procedures in ear, nose and throat operations.
Should investors sell immediately? Or is it worth buying Medtronic?
Days earlier, on October 1, the American Medical Association approved Category-I CPT codes for two Medtronic therapies: the Altaviva system for nighttime urinary urgency and the Symplicity Spyral renal denervation system for hypertension. Those billing keys take effect in January 2028 and establish a standardized foundation for future U.S. reimbursement. For Medtronic, such codes are pivotal — they open the door to routine coverage and broader clinical adoption across the American healthcare system.
Clinical Evidence Piles Up Across Segments
The reimbursement milestones rest on a growing body of clinical data. On October 3, at the VEINS 2026 conference, Medtronic presented worldwide prospective results from its VenaSeal Spectrum program, which examines the sealant system in advanced chronic venous disease. According to the company, expanded U.S. coverage now reaches 96 percent of individuals insured by commercial payers and Medicare.
Altaviva also received fresh support. On Tuesday, Medtronic released exploratory 24-month data from the TITAN 2 study, showing a sustained reduction in nocturia episodes among treated patients. For the post-approval ENDURANCE follow-up trial, Ariana L. Smith was named national principal investigator. In a separate push to raise awareness of pelvic floor disorders, the company forged a partnership with the American Urogynecologic Society.
Market Response
Investors took the operational news in stride. Medtronic shares finished Friday's session at EUR 79.00, up 1.0 percent on the day. Over the trailing seven-day stretch, the stock added 3.0 percent.
Ad
Medtronic Stock: New Analysis - 10 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
